Paratek Pharmaceuticals Inc. [NASDAQ: PRTK] stock went on an upward path that rose over 7.90% on Thursday, amounting to a one-week price increase of more than 10.96%. The company report on June 10, 2021 that Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus.
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced that it will host an investor webinar on Wednesday, June 16, 2021, at 10:00 a.m. Eastern Time.
During the webinar, Paratek will provide a corporate overview and an update on NUZYRA® (omadacycline), the company’s once-daily oral and intravenous antibiotic and discuss future development opportunities.
Over the last 12 months, PRTK stock rose by 131.57%. The average equity rating for PRTK stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $526.28 million, with 46.66 million shares outstanding and 42.91 million shares in the current float. Compared to the average trading volume of 448.18K shares, PRTK stock reached a trading volume of 1525276 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Paratek Pharmaceuticals Inc. [PRTK]:
WBB Securities have made an estimate for Paratek Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 23, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on March 02, 2021, representing the official price target for Paratek Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $19 to $22, while H.C. Wainwright kept a Buy rating on PRTK stock.
The Average True Range (ATR) for Paratek Pharmaceuticals Inc. is set at 0.50, with the Price to Sales ratio for PRTK stock in the period of the last 12 months amounting to 9.50.
PRTK Stock Performance Analysis:
Paratek Pharmaceuticals Inc. [PRTK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.96. With this latest performance, PRTK shares gained by 52.02% in over the last four-week period, additionally plugging by 55.26% over the last 6 months – not to mention a rise of 131.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRTK stock in for the last two-week period is set at 78.61, with the RSI for the last a single of trading hit 82.39, and the three-weeks RSI is set at 74.97 for Paratek Pharmaceuticals Inc. [PRTK]. The present Moving Average for the last 50 days of trading for this stock 8.08, while it was recorded at 10.16 for the last single week of trading, and 6.76 for the last 200 days.
Insight into Paratek Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Paratek Pharmaceuticals Inc. [PRTK] shares currently have an operating margin of -160.91 and a Gross Margin at +80.33. Paratek Pharmaceuticals Inc.’s Net Margin is presently recorded at -205.74.
Return on Total Capital for PRTK is now -40.30, given the latest momentum, and Return on Invested Capital for the company is -51.77. Additionally, PRTK Total Debt to Total Capital is recorded at 167.92, with Total Debt to Total Assets ending up at 142.56.
Reflecting on the efficiency of the workforce at the company, Paratek Pharmaceuticals Inc. [PRTK] managed to generate an average of -$490,056 per employee. Receivables Turnover for the company is 3.71 with a Total Asset Turnover recorded at a value of 0.22.Paratek Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 6.20.
PRTK Stock EPS
With the latest financial reports released by the company, Paratek Pharmaceuticals Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -783.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRTK.
Paratek Pharmaceuticals Inc. [PRTK] Insider Position Details
There are presently around $264 million, or 54.90% of PRTK stock, in the hands of institutional investors. The top three institutional holders of PRTK stocks are: BLACKROCK INC. with ownership of 3,478,440, which is approximately 0.902% of the company’s market cap and around 6.40% of the total institutional ownership; OMEGA FUND MANAGEMENT, LLC, holding 2,600,410 shares of the stock with an approximate value of $28.42 million in PRTK stocks shares; and VANGUARD GROUP INC, currently with $23.99 million in PRTK stock with ownership of nearly -0.968% of the company’s market capitalization.
Positions in Paratek Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 35 institutional holders increased their position in Paratek Pharmaceuticals Inc. [NASDAQ:PRTK] by around 1,673,622 shares. Additionally, 50 investors decreased positions by around 1,359,249 shares, while 33 investors held positions by with 21,123,625 shares. The mentioned changes placed institutional holdings at 24,156,496 shares, according to the latest SEC report filing. PRTK stock had 8 new institutional investments in for a total of 219,246 shares, while 10 institutional investors sold positions of 393,422 shares during the same period.